NeuroTalk Support Groups - Resources, Useful Websites & Clinical Trials

From the MSAA, "What's New in MS Research - May 2022":

What’s New in MS Research - May 2022 | MSAA

One of the articles may be noteworthy as it includes this:

Quote:

People receiving Ocrevus® (ocrelizumab) faced a 2.18 greater risk of developing COVID-19 post-vaccination relative to the general population, while those taking beta-interferon DMTs and glatiramer acetate (marketed as Copaxone® and by other names) had a lower risk than the general population. The post-vaccination risk of infection compared to that of the general population for people on other DMTs was:

Aubagio® (teriflunomide): 1.04
Mavenclad® (cladribine): 1.21
Tysabri (natalizumab): 1.22
Tecfidera® (dimethyl fumarate): 1.34
Gilenya® (fingolimod): 1.63

The investigators arrived at their findings by examining data on all 42,402 people in England who are receiving DMTs for treatment of MS. They found that more than 28,000 of those people had been tested for COVID-19, with 4,104 testing positive for coronavirus.

[Emphasis added]